Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Avacta Therapeutics logo — Expanding the reach of highly potent cancer therapies with t...

Avacta Therapeutics

Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.

Founded 2012 United Kingdom London, United Kingdom 48 employees Post-IPO Equity Biotechnology, Health Care +1

General Information

Company Name Avacta Therapeutics
Founded Year 2012
Location United Kingdom London, United Kingdom
Employees 48
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Business Model B2B, B2D
Revenue Model Licensing, Performance Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Avacta Therapeutics. To contact Avacta Therapeutics, visit avacta.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Avacta Therapeutics compare?

A PDF of Avacta Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Avacta Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Avacta Therapeutics

Avacta Therapeutics is a clinical stage biotechnology company founded in 2012 in the United Kingdom. Their mission, encapsulated in the slogan "Expanding the reach of highly potent cancer therapies with the pre|CISION® platform," reflects their focus on enhancing the effectiveness of cancer treatments.

The company operates within the Biotechnology, Health Care, and Pharmaceutical industries, making strides in the development of innovative cancer therapies. The pre|CISION® platform is at the heart of their offering, aiming to improve the targeting and delivery of cancer treatments for increased efficacy.

Notably, Avacta Therapeutics has yet to receive its last known investment as both the investment amount and investors remain undisclosed. This presents potential avenues for venture capitalists looking to participate in the expansion of cutting-edge cancer therapies, by backing a pioneering biotechnology entity poised to redefine traditional treatment modalities.

Business keywords: Cancer Therapies, pre|CISION® Platform, Biopharmaceutical Drug Development, Clinical Diagnostics, Analytical Tools, Animal Health, Protein Characterisation, Drug Discovery, Custom Antibody Alternatives, Affinity Reagents, Biophysical Technology, Life Science Markets, Subsidiaries

Services & Products

FAP-Activated Drug Development
Tumor-Specific Therapeutic Solutions
Research and Development in Oncology

Target Customers

Cancer Patients Healthcare Providers Oncology Researchers

No funding data available for Avacta Therapeutics yet.

Avacta Therapeutics Alternatives & Competitors

View All Alternatives
Avacta Therapeutics vs
Arcus Biosciences
Arcus Biosciences United States

Biopharmaceutical company developing differentiated molecules and combination therapies for cancer a...

IPO
633 employees
Biopharma, Biotechnology
Avacta Therapeutics vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
Avacta Therapeutics vs
Prelude Therapeutics
Prelude Therapeutics United States

Precision Oncology, Redefined.

Post-IPO Equity
126 employees
Biopharma, Biotechnology
Also compare with: Avacta Therapeutics vs Cellply Cellply View all alternatives

FAQ About Avacta Therapeutics

Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.
Avacta Therapeutics was founded in 2012.
Avacta Therapeutics is headquartered in London, United Kingdom.
Avacta Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Cancer Therapies, pre|CISION® Platform, Biopharmaceutical Drug Development and Clinical Diagnostics. Its customers include Cancer Patients, Healthcare Providers and Oncology Researchers.
Avacta Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing, Performance Based and Service Fee.
Avacta Therapeutics has approximately 48 employees.
Avacta Therapeutics offers: FAP-Activated Drug Development, Tumor-Specific Therapeutic Solutions, Research and Development in Oncology.
Top alternatives and competitors to Avacta Therapeutics include Arcus Biosciences, Oxford BioTherapeutics, Prelude Therapeutics, Bruker Dynamic Biosensors, Neogene Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Avacta Therapeutics and Arcus Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Avacta Therapeutics, https://bouncewatch.com/company/avacta-therapeutics, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout